Table of contents

Electronic pages

• PAF63 High prevalence of distal sensory polyneuropathy in treated and untreated Tanzanians with HIV. A cross-sectional survey (22 October, 2010)

  S Mullin, A Temu, S Kalluvya, A Grant, H Manji
• PAF64 Evaluation of a cysticidal treatment regime in an Indian population with neurocysticercosis (22 October, 2010)

  K K Dey
• PAF65 The growth of English neurology: more consultants, more appointments, still a lottery (22 October, 2010)

  P Morrish
• PAF66 Brain biopsy in neurological disease (22 October, 2010)

  C M Rice, C E Gilkes, E Teare, R J Hardie, N J Scolding, R J Edwards
• PAF67 Leukoaraiosis is unrelated to carotid stenosis or risk factors for atherosclerosis (22 October, 2010)

  U Schulz, T Meagher, P M Rothwell, D Briley, B Gruter, A Chandratheva
• PATH38 When is it safe to return to driving after a first-ever seizure? (22 October, 2010)

  W Brown, N Lawn, D Pearlman, S Shields, J Lee, E Somerville, J Dunne
• PATH39 Malformation risks of antiepileptic drugs in pregnancy: an update from the UK Epilepsy and Pregnancy Register (22 October, 2010)

  F Kennedy, J Morrow, S Hunt, A Russell, W H Smithson, L Parsons, I Robertson, B Irwin, N Delanty, P J Morrison, J Craig
• PATH40 Spectrum of clinical disease in hyperekplexia: the genotypes and phenotypes of 48 cases (22 October, 2010)

  R H Thomas, S K Chung, C L Hammond, A Robinson, M I Rees
• PATH41 Structural abnormalities, selection for epilepsy surgery and surgical outcome (22 October, 2010)

  U Wieshmann
• PATH42 Lineage, clinical, genetic, structural and cellular characterisation of a novel epilepsy mutation (22 October, 2010)

  J A Johnston, J S Davies, K Baer, C L Hammond, J G L Mullins, T D Cushion, S K Chung, R H Thomas, H R Morris, C White, P E M Smith, M I Rees
• PATH43 Hypoxic–ischaemic brain injury—MRI and EEG changes (22 October, 2010)

  R Howard, M Koutroumanidis, P A Holmes, A Siddiqui, I Tisopoulos, D Treacher
• PATH44 Corpus callosum diffusion tensor imaging as a biomarker for motor neurone disease (22 October, 2010)

  N Filippini, G Douaud, C E Mackay, S Knight, K Talbot, M R Turner
• PATH45 Cytoskeletal and inflammatory protein biomarkers for amyotrophic lateral sclerosis (22 October, 2010)

  J Ganesalingam, D Lacomis, J Lustgarten, C E Shaw, R Bowser, J An
• PATH46 Familial mutations in the RNA binding gene FUS result in cellular mislocalisation of the protein

  (22 October, 2010)

  B Rogelj, C E Shaw, C Vance, T Hortobagyi
• PATH47 Slow saccades in bulbar-onset motor neuron disease (22 October, 2010)

  C Donaghy
• PATH48 Morbidity and functional outcome in patients with Guillain–Barre syndrome admitted to the intensive care unit (22 October, 2010)

  S Weatherby, J S George, A Tillyard, A Sekhar, A Bradley, M Sittampalam
• PATH49 Use of intravenous immunoglobulin by neurologists in the UK: reporting from year 1 of the DoH IVIG database (22 October, 2010)

  M Lunn, A McManus, L Hyatt, D O'Shaughnessy, C Sewell
• PATH50 Novelty-seeking and risk-taking behaviour in subtypes of Parkinson's disease (22 October, 2010)

  V Singh-Curry, N Bunzeck, S O'Sullivan, M Molloy, R Perry, P Bain, A Lees, E Duzel, M Husain
• PATH51 Investigating adenosine A2A receptor availability in Parkinson's disease patients with and without levodopa induced dyskinesias with [11C]SCH442416 PET (22 October, 2010)

  A Ramlackhansingh, S K Bose, I Ahmed, N Pavese, D J Brooks, F E Turkheimer
• PATH52 Parkinsonism incidence in north-east Scotland: the PINE study (22 October, 2010)

  C Counsell, J Gordon, W Primrose, C Harris, R Caslake
• PATH53 Magnetic susceptibility of substantia nigra in Parkinson's disease: a 7-T in vivo MRI study (22 October, 2010)

  N Bajaj, A Schafer, S Wharton, V Gontu, R Bowtell, D P Auer, P Gowland, S Schwartz, A Lotfipour
• PATH54 Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study (22 October, 2010)

  K Bhatia, S A Schneider, L Silveira-Moriyama, J C Rothwell, K P Bhatia, P Schwingenschuh, P Katschnig, A J Lees, D Ruge, M J Edwards, N P Quinn
• PATH55 Characterising orthostatic tremor: a study of 56 patients (22 October, 2010)

  P Bain, L Jones
• PATH56 MRI correlates of vascular cognitive impairment: contribution of microbleeds, white matter changes and infarcts in a large hospital-based cross-sectional study (22 October, 2010)

  S Gregoire, L Cipolotti, N Sokolovsky, M M Brown, T A Yousry, D J Werring, H R Jaeger, K Smith, K Oaksford, G Scheffler
• PATH57 Altered structural and functional network connectivity predicts cognitive function after traumatic brain injury (22 October, 2010)

  D Sharp, Powell J Leech R, V Bonnelle, C F Beckmann, X De Boissezon, R Greenwood, K Kinnunen
• PATH58 Kappa and lambda free light chains in CSF in the differential diagnosis of multiple sclerosis and its correlation with clinical subtypes (22 October, 2010)

  S Jacob, A Karim, M Drayson, J Mitchell
• PATH59 Prognostic factors in untreated adult low-grade gliomas (22 October, 2010)

  J Rees, P S Tofts, J Czerny, J S Winston, A D Waldman, C E Benton, H R Jager
• PATH60 Demonstration of the time course of retrograde trans-synaptic degeneration in the visual system using optical coherence tomography (22 October, 2010)

  P Jindahra, G T Plant, A Petrie
• PATH61 Structural plasticity of white matter networks following anterior temporal lobe resection (22 October, 2010)

  M Yogarajah, A McEvoy, N Focke, J Duncan, M Koepp, M Symms, S Bonelli, P Thompson, C Vollmar
• PATU1 Characteristic faciobrachial dystonic seizures as an immunotherapy-responsive prodrome to voltage-gated potassium channel antibody-associated limbic encephalitis (22 October, 2010)

  S Irani, A W Michell, B Lang, A Vincent, E R Sommerville, M R Johnson, S M J Smith
• PATU2 Novel truncation mutation of PRNP causes chronic diarrhoea, sensory neuropathy and autonomic failure associated with prion protein deposition in the cerebral blood vessels and small bowel

  (22 October, 2010)

  S Mead, J Linehan, J Beck, D Caine, S Gandhi, J D F Wadsworth, S Joiner, D Gallujipali, H Hyare, A Lees, J Holton, M Sandberg, T Revesz, C Carswell, J D Warren, J Collinge, N Wood
• PATU3 Autoantibodies in “seronegative” myasthenia gravis (22 October, 2010)

  W J Zhang, M I Leite, A Vincent, A L Cox
• PATU4 A population-based longitudinal study of cognitive and behavioural impairment in amyotrophic lateral sclerosis (22 October, 2010)

  J Phukan, O Hardiman, N Jordan, L Gallagher, N P Pender
• PATU5 Characterisation of fused in sarcoma pathology and FUS mutations in juvenile amyotrophic lateral sclerosis with basophilic inclusions

  (22 October, 2010)

  K Talbot, J Lowe, O Ansorge, D Hilton, D Bäumer, S Paine, M Turner
• PATU6 Protein interactors of EAAT2 and their role in motor neurone disease/amyotrophic lateral sclerosis (22 October, 2010)

  K Morrison, E F Goodall, J Stockton, S Hill, Y Y Dong, C Moorby
• PATU7 Autoimmune diseases after alemtuzumab treatment for multiple sclerosis: findings from a multicentre UK cohort (22 October, 2010)

  M D Cossburn, A A Pace, J Jones, R Ali, G Ingram, K Baker, C Hirst, J Zajicek, N Scolding, M Boggild, T Pickersgill, A Coles, Y Ben-Shlomo, N P Robertson
• PATU8 Analysis of outcomes of high-dose immunosuppressive therapy with autologous stem cell transplantation in 156 patients with multiple sclerosis (22 October, 2010)

  V Novik, A N Kuznetsov, K A Kurbatova, R V Kruglina, T I Ionova, G V Gorodokin, D A Fedorenko, V Y Melnichenko
• PATU9 Seasonal variation in multiple sclerosis relapse (22 October, 2010)

  K Baker, T Pickersgill, N Robertson, M Cossburn, Y Ben-Shlomo, K Tilling, C Hirst, G Ingram
• PATU10 Neuromyelitis optica and related spectrum disorders in a UK population-based sample (22 October, 2010)

  G Tackley, M T Burtonwood, G Ingram, M D Cossburn, G A Malik, T Pickersgill, N P Robertson
• PATU11 IL2RA and CD226 genotypes influence multiple sclerosis disease outcome

  (22 October, 2010)

  T Mihalova, M Ban, A Baker, R Abraham, R Strange, C P Hawkins
• PATU12 Acute central nervous system infections in adults—a retrospective cohort study in the NHS northwest region (22 October, 2010)

  B Michael, N J Beeching, M Sidhu, M Roberts, A Bonington, I J Hart, R Kneen, A Miller, T Solomon, D Stoeter
• PAW13 Drug-class effects on consistency of control of blood pressure and hence on stroke risk: systematic review of 1372 trials (22 October, 2010)

  A Webb, P M Rothwell, U Fischer, Z Mehta
• PAW14 Major unmet need for more effective secondary prevention in the subacute phase after minor ischaemic stroke: a population-based study (22 October, 2010)

  N L M Paul, A Chandratheva, O C Geraghty, P M Rothwell
• PAW15 Screening patients with a family history of subarachnoid haemorrhage for intracranial aneurysms: screening uptake, patient characteristics and outcome (22 October, 2010)

  T Miller, R Al-Shahi Salman, R J Davenport, P M White
• PAW16 Actual workload of acute stroke thrombolysis: how many patients need to be assessed for each one treated? (22 October, 2010)

  S J Slaght, A Keens, N U Weir, J K Lovett
• PAW17 Recurrent transient ischaemic attack, capsular warning syndrome, ABCD2 score and early risk of stroke: a population-based study (22 October, 2010)

  N L M Paul, A Chandratheva, P M Rothwell
• PAW18 Blood markers and the diagnosis of stroke or transient ischaemic attack in the emergency department: a prospective cohort study (22 October, 2010)

  W Whiteley, G D Lowe, N Rumley, J M Wardlaw, V Green, P Welsh, M S Dennis, P A G Sandercock
• PAW19 Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease (22 October, 2010)

  C Carroll, G J Williams, N H Chadborn, C O Hanemann, J P Zajicek, K E Morrison, K Gibson, M Zeissler
• PAW20 Saccadic correlates of cognition in progressive supranuclear palsy (22 October, 2010)

  B Ghosh, J B Rowe, R H S Carpenter, A J Calder, P V Peers, A D Lawrence, J R Hodges
• PAW21 Rewarding visual cues increase dopamine neurotransmission in Parkinson's patients with impulse control disorders: a PET study (22 October, 2010)

  K Wu, S O'Sullian, M Politis, S Bose, A Lees, P Piccini
• PAW22 Does cortical atrophy take place after basal ganglia damage in multiple system atrophy and progressive supranuclear palsy? (22 October, 2010)

  C Guevara, N Deasy, C A Payan, J Jarosz, Y Agid, P N Leigh, A Ludolph, M J Kempton, G Barker, G Bensimon
• PAW23 Voxel-based analysis of magnetisation transfer ratio as a potential biomarker in prion diseases (22 October, 2010)

  H Hyare, R Scahill, J S Thornton, J Collinge, D Siddique, C Carswell, E De Vita, T Yousry, P Rudge, S Mead
• PAW25 A single-centre, pilot, randomised controlled trial of recombinant human erythropoietin in primary progressive multiple sclerosis (22 October, 2010)

  I Karpha, J Ramtahal, M Boggild, F Evans
• PAW26 Are the beneficial effects of Botulinum toxin for refractory detrusor overactivity in multiple sclerosis sustained with repeat injections?

  (22 October, 2010)

  J Panicker, S Khan, X Game, C Dalton, G Gonzales, S Elneil, R Hamid, C Fowler
• PAW27 Age-dependent phenotypic variation of multiple sclerosis at disease onset (22 October, 2010)

  M Cossburn, C L Hirst, T P Pickersgill, N P Robertson, Y Ben-Shlomo, G Ingram
• PAW28 The natural history of multiple sclerosis, a geographically based study. 10: relapses and long-term disability (22 October, 2010)

  G Ebers, A Neuhaus, P Muraro, M Daumer, N Harner, A Degenhardt, G P Rice, A Scalfari
• PAW29 Multiple sclerosis in Ireland: regional variation in prevalence and vitamin D status (22 October, 2010)

  R Lonergan, S Jordan, R Hagan, K Kinsella, P Fitzpatrick, M Duggan, B Murray, M McKenna, M Hutchinson, N Tubridy, J Brady, C Dunne
• PAW30 Impact of genome-wide association screening on the genetics of multiple sclerosis (22 October, 2010)

  S Sawcer
• PAW31 Clinical and genetic spectrum of the episodic ataxias: the UK perspective (22 October, 2010)

  S Rajakulendran, R W Labrum, T D Graves, S Tomlinson, L H Eunson, M B Davis, S Schorge, D M Kullmann, M G Hanna
• PAW32 ITPR1 gene deletion causes spinocerebellar ataxia 15/16: a genetic, clinical and radiological description of a novel kindred

  (22 October, 2010)

  M Novak, M Davis, A Li, R Goold, S J Tabrizi, M G Sweeney, H Houlden, C Treacy, P Giunti
• PAW33 Aquaporin-4 M 23 isoform provides a more sensitive assay for aquaporin-4 antibodies (22 October, 2010)

  P Waters, M I Leite, B Gray, A Vincent, Y Jiang, J Palace
• PAW34 Mutations in OPA1 expand the clinical phenotype of mitochondrial disease

  (22 October, 2010)

  P Chinnery, M Jackson, P Amati-Bonneau, P Yu-Wai-Man, G Gorman, P Duffey, M Baker, M Zeviani, R Horvath, J Miller
• PAW35 Anti-prion protein monoclonal antibodies at low doses effectively treat prion disease in mice without side-effects (22 October, 2010)

  C Carswell, A Khalili-Shirazi, S Brandner, S Martins, R Drynda, J Collinge, S Mead, A Clarke
• PAW36 Oculomotor deficits in presymptomatic and early Huntington's disease and their structural brain correlates (22 October, 2010)

  S Hicks, H D Rosas, C Berna, R Scahill, E Durmas, R A Roos, B Levitt, S J Tabrizi, C Kennard, A Durr
• PAW37 Microarray analysis identifies the gene signature of spared vs vulnerable motor neurone groups (22 October, 2010)

  E Wood, P Heath, P Shaw
• CP1 Darkness visible (22 October, 2010)

  R Dobson, M Lawden
• CP2 A portrait of the artist as a young woman with parkinsonism: a clinical and videographic record of pallidopontonigral degeneration (22 October, 2010)

  S O'Dowd, H Kearney, R Walsh, T Lynch, B Magennis
• CP3 Progressive ataxia with unusual radiographic findings (22 October, 2010)

  C Marshall, G Giovannoni
• CP4 Isolated sleep paralysis as a presenting feature of obstructive sleep apnoea (22 October, 2010)

  G Leschziner, R S Howard, A Williams, C Kosky
• CP5 She's going blind! (22 October, 2010)

  J Chan, A Kinderlerer, J Chataway
• CP6 Anopthalmia and dysembryoplastic neuroepithelial tumours in a family with Noonan syndrome and a novel PTPN11 mutation

  (22 October, 2010)

  R Mir, K Chong, C Benett, A Aldin, F Balen, A Kraus, R Taylor
• POC01 A case presentation that highlights the significance of peripheral eosinophilia in patients presenting with a mononeuritis (22 October, 2010)

  M Sittampalam, V Apostu, M J Sadler
• POC03 Vanishing gliomatosis or two separate pathologies? (22 October, 2010)

  K Abdel-Aziz, R Benson, R Manohar, R P White, A Barborie
• POC04 From atrophy to dystrophy—an unusual route to diagnosis through an integrated clinical assessment and treatment service (22 October, 2010)

  S Chhetri, M E Roberts, J Sussman
• POC05 An unusual case of postpartum coma (22 October, 2010)

  S Muzerengi, A Salek-Haddadi
• POC06 “YOU'LL HAVE TO SPEAK UP DOC…” an unusual after-effect of interventional neuroradiology (22 October, 2010)

  R Konduri, R Powell, T A T Hughes, S Halpin, T P Pickersgill
• POC07 Central nervous graft-vs-host disease causing intracranial vasculopathy (22 October, 2010)

  S Kearney, A J Fulton, M F McMullin, E McKenna
• POC08 A case of central and peripheral vestibular vestibular failure (22 October, 2010)

  K M C Doherty, H Ling, E Mulroy, Y Foung-Tai, A Djamshidian, L Silveria-Moriyama, L Massey, S Brew, A J Lees
• POC09 Effects of an attending physician system on acute neurology provision in Plymouth (22 October, 2010)

  M Sadler, S Edwards, S Weatherby, A Mohd Nor, S Allder
• POC10 The dark night: a family diagnosis (22 October, 2010)

  C Walker, R H Thomas, P E M Smith
• POC11 Multiple radiculopathies and cranial nerve palsies in association with chronic lymphocytic leukaemia and lupus anti-coagulant treated with rituximab (22 October, 2010)

  J Morrow, R Page, M Al Hilali, S D'Sa, M M Reilly
• POC12 Not my diagnostic area? (22 October, 2010)

  R Powell, N P Robertson
• POC13 Guillain–Barre syndrome following aneurysmal subarachnoid haemorrhage: first case report (22 October, 2010)

  V Apok, K Ghosh, P Gunawardena, N Gurusinghe
• POC14 Treatment-resistant hyponatraemia (22 October, 2010)

  S Huda, H Tyne, A G Marson
• POC15 An unexpected result in a patient with subacute meningoencephalitis and severe intracranial hypertension (22 October, 2010)

  F Rossiter, J Nicholl, A Vincent, L Kinton, S Viegas, M Prevett
• POC16 Syndrome of inappropriate antidiuretic hormone precipitated by steroid responsive demyelinating neuropathy (22 October, 2010)

  L Varadhan, T Mihalova, P Newman, D Barton
• POC17 Treacherous triangle of tumour, seizure and stroke (22 October, 2010)

  K Krolikowski, O Hanemann, J Jones
• POC18 An encephalopathy worth its salt (22 October, 2010)

  K Ali, O R Pearson, J A Johnston, V Sawlani
• POC19 Anti-Hu paraneoplastic sensory neuronopathy with underlying squamous cell carcinoma of the lung (22 October, 2010)

  P Gozzard, D Soon, A Vincent, B Lang
• POC20 Do patients like being present when their letters are dictated, and does it matter? (22 October, 2010)

  R De Silva, A Misbahuddin, K Grayson, S Mikhail
• POC21 Posterior reversible encephalopathy syndrome in a case of leptospirosis (22 October, 2010)

  J Aram, O C Cockerell, J Evanson
• POC22 Optic neuropathy secondary to sphenoid fungal sinusitis (22 October, 2010)

  S H Wong, A C Swift, T Helliwell, K Das, T P Enevoldson
• POC23 Venous sinus stenting in a patient with multiple meningiomata—a case report (22 October, 2010)

  P D Shanmugarajah, T J Hodgson, J N P Higgins, I M Pepper, S J Hickman
• POC24 Subspeciality demand in a regional neurology service (22 October, 2010)

  E Newman, J Overell, J P Leach, R Garscadden, M E Farrugia, G Gorrie, S R Thomas
• POC25 B-cell non-Hodgkin lymphoma presenting with diplopia, ataxia, and subacute polyneuropathy: neoplastic vs paraneoplastic? (22 October, 2010)

  S Huda, H Tyne, I Iniesta
• POC26 A protracted course of neuroborelliosis, the debate continues (22 October, 2010)

  S Huda, M F Afzal, H Tyne, U C Wieshmann
• POC27 Addressing functional symptoms in neurology: can outpatient intervention make a difference? (22 October, 2010)

  S Samarasekera, R J Abbott
• POC28 A rare reversal in neurology (22 October, 2010)

  S Little, A Al-Memar
• POC29 Case report: trigeminal amyloidoma in a 50-year-old man (22 October, 2010)

  S Elliott, P Rich, A Al-Memar
• POC30 Telemedicine—a useful tool to link people with complex disabilities to specialist neurological services (22 October, 2010)

  V Stevenson, E Keenan, K Nutman, M Koch
• POD01 Misleading MRI in two recent patients with variant Creutzfeldt–Jakob disease emphasises the importance of tissue diagnosis (22 October, 2010)

  A Lukic, J Wadsworth, S Brandner, P Rudge, H Hyare, J Collinge, L Reiniger, S Mead, C Gilmore, M Humberstone
• POD02 Predicting brain atrophy at 1 year by baseline multimodal MRI data (22 October, 2010)

  A Tarunya, S Smith, M Jenkinson, J A Palace, C Beckmann
• POD03 Distinct neuropsychological profiles correspond to distribution of cortical thinning in inherited prion disease caused by insertional mutation (22 October, 2010)

  P Rudge, N C Fox, L Cipolotti, S Mead, H Hyare, J Rohrer, J Collinge
• POD04 Analysis of eight rating scales supports the use of functional outcome measures in prion disease clinical trials: experience from the PRION-1 trial and the National Prion Monitoring cohort (22 October, 2010)

  A Thompson, P Rudge, S Wroe, S Mead, J Darbyshire, A MacKay, M Ranopa, J Collinge, G Gopalakrishnan, S Walker
• POD05 Impairment of vestibular memory in a patient with a right hippocampal lesion (22 October, 2010)

  B Seemungal, A M Bronstein, D Chan, D Kaski
• POD06 Human pedunculopontine nucleus displays vestibular reactivity (22 October, 2010)

  B Seemungal, N Yousif, A M Bronstein, J Naushahi, D Nandi
• POD07 Tinnitus and hyperacusis in semantic dementia (22 October, 2010)

  C Mahoney, M N Rossor, J D Rohrer, J D Warren, N C Fox, J C Goll
• POD08 Abnormal saliency processing in a patient with visual form agnosia (22 October, 2010)

  S Mannan, C Rosenthal, C Kennard, R Graham, S Hicks
• POD09 Using the chick embryo model system to study the neurotoxicity of TDP43 (22 October, 2010)

  V Tripathi, S Guthrie, C Shaw, V Marinela, A Al-chalabi, C Vance, J Sreedharan
• POD10 Demonstration of optic tract atrophy in hemianopia by magnetic resonance imaging: confirmation of retrograde trans-synaptic degeneration in the human visual pathway (22 October, 2010)

  G Plant, J Barbur, P Jindahra, H Bridge
• POD11 Altered peroxiredoxin antioxidant enzyme expression in activated and quiescent human astrocytes (22 October, 2010)

  N Gutowski, P G Winyard, K Szabo-Taylor, J E Holley
• POD12 Development of a hands-free, eye-tracking version of the Trail Making Test (22 October, 2010)

  R Sharma, S Hicks, A Khan, C Berna, C Kennard, K Talbot, M R Turner
• POD13 White matter connectivity in semantic dementia (22 October, 2010)

  M Jones, D Neary, K Embleton, J Snowden, K Herholz
• POD14 Amyloid PET using 18F-AV-45 in Alzheimer's disease and frontotemporal dementia: first UK results (22 October, 2010)

  E R L C Vardy, T Langheinrich, R Hinz, J S Snowden, A Gerhard, A M T Richardson, D Neary, J Anton, G D Brown, K Herholz
• POE01 Outcome of medication change in patients with refractory epilepsy (22 October, 2010)

  S H Wong, D F Smith, A G Marson
• POE02 Postoperative reduction in anti-epileptic drugs cost (22 October, 2010)

  J Giles
• POE03 EEG and imaging correlates of insular seizures (22 October, 2010)

  O Jumma, A Varma
• POE04 Incidence, prevalence and risk factors for death in epilepsy: a population cohort, nested case control study (22 October, 2010)

  L Ridsdale, M Gulliford, M Richardson, J Charlton, M Ashworth
• POE05 A low creatinine in developmental delay, epilepsy and movement disorders—does it matter? (22 October, 2010)

  C Hinnell, Y Rahman, F Alkufri, M Samuel, C Turner, N Dalton, L Nashef
• POE06 The teenage epilepsy clinic: an observational study (22 October, 2010)

  C A Hilditch, R H Thomas, F Gibbon, P E M Smith
• POE07 Ambulatory care pathway for suspected first seizure patients attending the emergency department (22 October, 2010)

  M Sadler, V Apostu
• POE08 Generalised (or genetic) epilepsy with febrile seizures plus phenotypes of definite and borderline UK families (22 October, 2010)

  J A Johnston, R H Thomas, C L Hammond, S Bagguley, C White, P E M Smith, M I Rees
• POG01 Anti-thymidine phosphorylase antibodies in the diagnosis of mitochondrial neurogastrointestinal encephalomyopathy (22 October, 2010)

  L Ginsberg, J W Taanman
• POG02 Variant ataxia telangiectasia in siblings with normal α-fetoprotein levels (22 October, 2010)

  C Albertyn, N Cawley, A T M Taylor, V Srinivasan, J I Last, R P Murphy
• POG03 Identification of a novel SCA 14 mutation in an Irish family

  (22 October, 2010)

  C Albertyn, R P Murphy, A Rolfs, A Lakhani
• POG04 Multiple mitochondrial DNA deletions, cyclooxygenase-negative fibres and slowly progressive cognitive decline with psychiatric features (22 October, 2010)

  S Rajakulendran, R D S Pitceathly, J Warren, C Woodward, M G Sweeney, I Hargreaves, C Fratter, S Heales, R Taylor, J L Holton, S Rahman, M G Hanna
• POG05 Habitual physical activity in mitochondrial disease—do we need to intervene? (22 October, 2010)

  G Gorman, S Apabhai, J L Elson, M I Trenell, D M Turnbull
• POG06 Development and validation of a quality of life scale for mitochondrial disease (Mito-QoL) (22 October, 2010)

  G Gorman, D M Turnbull, R Horvath, R Whittaker, A Phillips, M Cadogan, J L Elson, E McColl, S Apabhai, R MaFarland
• POG07 Natural history trials of neurological channelopathies (22 October, 2010)

  S Rajakulendran, E Matthews, T D Graves, S V Tan, L Dewar, R C Griggs, M G Hanna
• POG08 Novel mitochondrial tRNA mutation associated with migraine, pigmentary retinopathy, leukoencephalopathy and sensorineural deafness (22 October, 2010)

  J Panicker, R W Taylor, E L Blakely, M Wilson
• POG09 CADASIL in a mother and son due to a novel mutation of the NOTCH-3 gene

  (22 October, 2010)

  C Hewamadduma, K A Harkness, D K Chadha, A Dalton, C J McDermott
• POG10 Fragile X premutation causing propriospinal myoclonus: response to selective serotonin reuptake inhibitor (22 October, 2010)

  S Wong, A Selvan, R P White
• POG11 A novel mutation in the nerve-specific 5′-UTR of the Cx32 gene causing CMTX1

  (22 October, 2010)

  S Murphy, S Brandner, J Polke, H Manji, H Houlden, M M Reilly
• POG12 Ataxia–telangiectasia: mild and slowly progressive clinical presentation associated with two null ATM alleles

  (22 October, 2010)

  P Worth, A M R Taylor
• POH01 Is pregabalin helpful for managing headache and facial pain? (22 October, 2010)

  M Weatherall
• POH02 Impact of chronic vs episodic migraine on disability, health-related quality of life and healthcare resource utilisation in the UK (22 October, 2010)

  P J Goadsby, R B Lipton, S F Varon, D C Buse, A K Kawata, T K Wilcox, A Blumenfield, I Girod
• POH03 A face marred by sweat: only half the story (22 October, 2010)

  K Ali, J A Johnston, S Fareedi, N Hinds
• POH04 Treatment of medically intractable SUNCT and SUNA with occipital nerve stimulation (22 October, 2010)

  M Matharu, L Watkins, P Shanahan
• POH05 Efficacy and safety of greater occipital nerve blocks in cluster headache (22 October, 2010)

  M Matharu, U Khan, S McCulloch, P Shanahan
• POH06 Headache management: greater occipital nerve injection as part of clinical practice (22 October, 2010)

  K Krolikowski, S Weatherby
• POH07 Use of complementary and alternative medicine by patients attending a UK headache clinic (22 October, 2010)

  T Lambert, J Edwards, C E Clarke, K E Morrison
• POI01 Direct comparison of multiple nonlesional imaging measures to assess their power to measure treatment effects over 1 year in primary progressive multiple sclerosis (22 October, 2010)

  T Arun, S Smith, A P Weir, J Palace, M Jenkinson
• POI02 Fulminant cerebellitis related to H1N1: a first case report (22 October, 2010)

  V Apok, A Alamri, A Qureshi, B Donaldson-Hugh
• POI03 Using natalizumab in highly active relapsing remitting multiple sclerosis in the UK (22 October, 2010)

  R Nicholas, C D'Arcy, P Muraro, C McGuigan, O Malik, P Giannetti, S O'Driscoll
• POI04 Transverse myelitis—a single centre review (22 October, 2010)

  J Panicker, A Jones, A Jacob
• POI05 StayingSmart—an online web resource about cognitive deficits in multiple sclerosis for patients, carers and professionals (22 October, 2010)

  D Langdon, N Russell, A Field, L Fox
• POI06 Rituximab in neuropsychiatric systemic lupus erythematosus: a retrospective study of the Cambridge experience (22 October, 2010)

  M Zandi, F Catapano, S Burns, F C Hall, K G C Smith, D R W Jayne, A J Coles
• POI07 Recurrent N-methyl-d-aspartate receptor encephalitis: a case report

  (22 October, 2010)

  J E Spillane, N P Hirsch, C Taylor, R Howard
• POI08 Serum C4a levels in multiple sclerosis correlate with disease activity (22 October, 2010)

  G Ingram, B P Morgan, N P Robertson, S Hakobyan
• POI09 Trends in BK and JC polyomavirus and relationship to CD4+/CD8+ ratio in patients with relapsing remitting multiple sclerosis on natalizumab therapy (22 October, 2010)

  A Molloy, K Kinsella, N Turbridy, M Hutchinson, M Duggan, C F De Gascun, R Lonergan, J Stack, W Hall
• POI10 Using atypical symptoms to predict nondemyelinating disease in patients as “query multiple sclerosis” (22 October, 2010)

  S Kelly, N Turbridy, Hutchinson
• POI11 The MS-STAT trial: a phase II trial of high-dose simvastatin for secondary progressive multiple sclerosis: baseline trial profile (22 October, 2010)

  J Chataway, V Anderson, D Chan, C Frost, K Hunter, C Kallis, J Greenwood, N Schuerer, A Alsanousi, R Nicholas
• POI12 Electrophysiological sensory demyelination in typical chronic inflammatory demyelinating polyneuropathy (22 October, 2010)

  S Samarasekera, Y A Rajabally
• POI13 Acute respiratory failure in a multiple sclerosis relapse: successful treatment with plasma exchange (22 October, 2010)

  M Maguire, P Newman, J Fuller
• POI14 Multiple sclerosis: a potential association with anti-N-methyl-d-aspartate receptor encephalitis

  (22 October, 2010)

  J Johnston, K Ali, O R Pearson, C Rickards, A Vincent
• POI15 Unusual brain cysts: a massive clinical problem (22 October, 2010)

  K Baker, T P Pickersgill
• POI16 Comparing MRI measures of myelin integrity as surrogate markers for the clinical expression of primary progressive multiple sclerosis (22 October, 2010)

  L Matthews, J Palace, S Deoni, M I Leite, H Johansen-Berg, S H Kolind
• POI17 Dramatic radiological improvement in isolated neurosarcoidosis treated with infliximab (22 October, 2010)

  J L Kitley, I Galea, M L Gawne-Cain, W R G Gibb
• POI18 Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis (22 October, 2010)

  R Dobson, M Feldmann, A J Thompson, G Giovannoni, D H Miller, E J Thompson, H E Palmer, R F Miller
• POI19 EBNA-1 IgG is not a reliable clinical marker of multiple sclerosis disease activity (22 October, 2010)

  G Ingram, J J Bugert, S Loveless, N P Robertson
• POMD01 Blinded analysis of conventional MRI in a cohort of pathologically confirmed parkinsonian illnesses (22 October, 2010)

  L Massey, D C Paviour, N C Fox, C Micallef, D J Burn, J L Holton, A J Lees, H R Jager, T Revesz, S S O'Sullivan
• POMD02 Degree and clinical correlates of cerebral small vessel vascular disease in incident parkinsonian patients (22 October, 2010)

  D M A Swallow, C E Counsell, A D Murray
• POMD03 Association of head injury with Parkinson's disease risk by age at onset (22 October, 2010)

  M Perera, Y Ben Shlomo, M M Wickremaratchi, R Salmon, H R Morris
• POMD04 Utility of temporal discrimination threshold testing in different adult-onset primary torsion dystonia phenotypes (22 October, 2010)

  D Bradley, R Whelan, F Molloy, S Hutchinson, M Hutchinson, N Mulrooney, R Reilly, R Walsh
• POMD05 Temporal discrimination threshold in patients with sporadic adult-onset primary torsion dystonia and their first degree relatives (22 October, 2010)

  D Bradley, R Whelan, F Molloy, S Hutchinson, M Hutchinson, N Mulrooney, R Reilly, R Walsh
• POMD06 Utility of visual, tactile and mixed tasks in the determination of temporal discrimination thresholds in adult-onset primary torsion dystonia (22 October, 2010)

  D Bradley, R Whelan, F Molloy, S Hutchinson, M Hutchinson, N Mulrooney, R Reilly, R Walsh
• POMD07 Quantitative assessment of biological and clinical manifestations of Huntington's disease before and after diagnosis—the TRACK-HD study (22 October, 2010)

  N Lahiri, S J Tabrizi, C Kennard, A Durr, B R Leavitt, N Fox, R A Roos
• POMD08 Zebrafish models for early onset Parkinson's disease (22 October, 2010)

  O Bandmann, L Flinn, H Mortiboys
• POMD09 Understanding the early pathological pathways in Parkinson's disease. The Oxford Parkinson's Disease Centre (22 October, 2010)

  M Hu, C Ponting, C Mackay, K Talbot, R Wade-Martins, M Wood, J P Bolam, Y Ben-Shlomo, O Ansorge, W James
• POMD10 Do psychiatric disorders form part of the myoclonus-dystonia syndrome phenotype? A systematic review of published literature (22 October, 2010)

  K Peall, D Perera, D J Blake, M J Owen, H R Morris
• POMD11 Cannabinoids are neuroprotective in a human cell culture model of Parkinson's disease (22 October, 2010)

  C Carroll, J P Zajicek, C O Hanemann, V Stone, M Zeissler
• POMD12 Visual cue “walking glasses” may aid gait in Parkinson's disease (22 October, 2010)

  J McAuley, P Daly, C Curtis
• POMD13 Distinguishing tremor-dominant Parkinson's disease from tremulous subjects without evidence of dopaminergic deficit by spirography: an FP-CIT validated study (22 October, 2010)

  P Bain, M Knobel, V Gontu, N P S Baja
• PONM01 Measurement of global strength: stable concept, fluid ruler (22 October, 2010)

  A Pace, J C Hobart, J P Zajicek
• PONM02 Grading strength in manual muscle testing: bespoke works better (22 October, 2010)

  A Pace, J C Hobart, J P Zajicek
• PONM03 Neuralgic amyotrophy and viral infections are important causes for phrenic nerve palsy and surgery is effective treatment (22 October, 2010)

  A Al-Saleh
• PONM04 Myofibrillar myopathy caused by a mutation in the desmin gene: expanding the phenotype

  (22 October, 2010)

  C Albertyn, C Maguire, R P Murphy
• PONM05 An unusual presentation of McArdle's disease (22 October, 2010)

  Y Liang
• PONM06 Plasma neurofilament heavy chain levels as a disease biomarker in the SOD1 mouse model of amyotrophic lateral sclerosis

  (22 October, 2010)

  C Lu, A Malaspina, R Orrell, B Kalmar, A Petzold, L Greensmith
• PONM07 Nerve excitability parameters are biomarkers that differentiate between voltage-gated sodium blockers with differential mode of action (22 October, 2010)

  K Shields, M Koltzenburg
• PONM08 Late recurrent thymoma: a case series (22 October, 2010)

  J Spillane, D M Kullmann, C Taylor, N P Hirsch
• PONM09 Thymectomy: its role in the management of myasthenia gravis (22 October, 2010)

  J Spillane, D M Kullmann, C Taylor, N P Hirsch, R Howard
• PONM10 Motor neurone disease. Experience and expectations of patients and care givers (22 October, 2010)

  M Tanaka Gutiez, B Nevin, J Stewart, L Jarrett, S J M Weatherby
• PONM11 “The eyes have it”: initial genetic screening in suspected congenital myasthenia (22 October, 2010)

  D Lashley, G Burke, D Beeson, J Palace
• PONM12 Multifocal motor neuropathy due to infliximab (22 October, 2010)

  S Kelly, S Connolly, A McCarthy, M Hutchinson, S Murphy, N Turbridy
• PONM13 Fatty acid oxidation disorders in adults: a potentially treatable cause of muscle disease (22 October, 2010)

  R Pitceathly, S Rahman, C Maritz, M G Hanna, R Lachmann, E Murphy
• PONM14 A novel homozygous missense mutation in the GNE gene of two brothers with hereditary inclusion body myopathy type 2

  (22 October, 2010)

  U M Sheerin, R J M Lane, W Rakowicz, F Roncaroli
• PONM15 A reversible cause of “fasciculation”, muscle wasting and encephalopathy (22 October, 2010)

  S Hughes, S Haffey, J McConville, A S Carr, K M C Doherty, S A Hawkins
• PONM16 Unusual surgery for progressive finger-drop (22 October, 2010)

  U Khan, S Murphy, M Lunn, D Hrouda, M Seckl, J Ball, C Alifrangis, C Gabriel, S Hazel, M M Reilly
• PONM17 Augmentation of the heat shock response in an in vitro model of sporadic inclusion body myositis (22 October, 2010)

  A Miller, M Ahmed, M G Hanna, L Greensmith
• PONM18 Nerve excitability studies can be used to differentiate between voltage-gated sodium blockers using an in-vitro cutaneous sensory nerve model: potential prospects as a model for drug discovery (22 October, 2010)

  K Shields
• PONM19 The ALS Online Genetics Database (22 October, 2010)

  O Abel, A Al-Chalabi, P Anderson, J Powell
• PONM20 Should acetylcholine receptor antibody requesting be restricted to hospital clinicians? No difference demonstrated in the proportion of positive assay results between primary and secondary care (22 October, 2010)

  C E M Hillier, P Massey, A Durnford, N Owen
• PONM21 Electron microscopy does not add to the diagnostic accuracy of muscle biopsy for suspected mitochondrial disease (22 October, 2010)

  T Graves, R Phadke, J L Holton, M G Hanna, S Rahman, N Bhardwaj
• PONM22 An investigation into the diagnosis and further management of chronic idiopathic polyneuropathies (22 October, 2010)

  K Stevens, M Reilly, A Almemar
• PONM23 The falling incidence of ITU admission in myasthenia gravis: does the early introduction of immunosuppression save lives? (22 October, 2010)

  C McHugh, J D Sussman
• PORT02 Oxford motor neurone disorders research (22 October, 2010)

  K Talbot, M R Turner
• PORT03 MRC mitochondrial cohort study: development of a UK database (22 October, 2010)

  R Pitceathly, R McFarland, V Nesbitt, S Rahman, M G Hanna, D M Turnbull
• PORT05 Medical students value an integrated approach to clinical neurology training (22 October, 2010)

  J A Giles, A Kirby
• PORT06 Neurophobia and undergraduate neurology training (22 October, 2010)

  J A Giles, A Kirby
• POS01 Rankin scales for measuring stroke outcomes: is it time to throw in the towel? (22 October, 2010)

  J Hobart, D Andrich
• POS02 Moyamoya disease: a UK single centre experience (22 October, 2010)

  V Apok, K Ghosh, A Alamri
• POS03 Validity of CT vs MR brain imaging in studies of risk factors for leukoaraiosis: a systemic review (22 October, 2010)

  M Simoni, P M Rothwell, Z Mehta
• POS04 Simple functional scales miss significant cognitive impairment: implications for assessing outcome after stroke (22 October, 2010)

  S Pendlebury, P M Rothwell, J Mariz, Z Mehta, F Baig
• POS05 Impairment on Montreal Cognitive Assessment in transient ischaemic attack and stroke patients with normal Mini-Mental State Examination score is clinically relevant (22 October, 2010)

  S Pendlebury, P M Rothwell, J Mariz, Z Mehta
• POS06 Subarachnoid haemorrhage: 13 years of litigation in the NHS (22 October, 2010)

  I Buchanan, A Sekhar, M Sittampalam, S Weatherby
• POS07 Reduced ADAMTS-13 activity levels in partial anterior circulation transient ischaemic attack patients compared to nonstroke controls (22 October, 2010)

  G A Frentzou, C Kamara, K A Harkness, G Haddock, C Doyle, M Taylor, G S Venables, M N Woodroofe, A K Cross, M Randall
• POS08 Does the association of the ABCD2-score with leukoaraiosis explain its prognostic value? (22 October, 2010)

  U Schulz, B E Gruter, A Chandratheva, T Meagher, D Briley, P M Rothwell
• POS09 Vertebral and carotid dissections: different clinical entities (22 October, 2010)

  R Rolph, M Waltham, L Corfield
• POS10 Variability in patient response to clopidogrel and effects on outcome from carotid stenting (22 October, 2010)

  M Randall, R F Storey, G S Venables, P A Gaines, T J Cleveland
• POS11 Blood markers and poor outcome after acute cerebrovascular disease: a prospective cohort study (22 October, 2010)

  W Whiteley, A Rumley, N Sattar, J M Wardlaw, G D O Lowe, P Welsh, A Green, P A G Sandercock, M S Dennis
• POS12 Telemedicine is as safe as bedside delivery for thrombolysis in acute stroke (22 October, 2010)

  S Pollock, N Munro, D Hargroves, S Manjunathan, P Pullicino, J Karlsson, G Gunathilagan, I Burger, H Baht, S Pollock, W Ogburn, G Thomas